Praluent is SUNK!!!!

Anyone with half a brain can figure out that the ODYSSEY results are far from incredible. If there was a significant separation from the control group, whether good or bad, the Drug Safety Monitoring Board would have stopped the trial early. It is unethical to let it continue if there is clearly better mortality evidence with one group. When the results are announced there will be a spin to make it sound so wonderful. The presentation will talk about a lot of relative risk reductions that sound impressive vs talking absolute risk reduction. Intelligent Cardiologists like to hear about Absolute Reductions because it is not just fluff.

The needle will not move in a positive direction with this reveal. Managed Care companies and doctors want mortality benefit to justify high price tag. The PCSK9s will take a hit as a class. However, Amgen will win injunction case against Sanofi/Regeneron later this year.

 

Spot on with most of your analysis.
The only thing you are wrong about is the new court case later this year.
Amgen will not prevail.

 

The OP might be right on all counts. Amgen recently tried to reverse the Appeals Court ruling which said another trial is necessary. The ruling found that certain evidence should not have been disclosed to the jury. The court found merit in the injunction but felt there was a procedural error. The court case shouldn’t take that long for Amgen to win. However, when the results of this trial are released Amgen may decide not to throw good money after bad. This ship is sinking either way. Plus Sanofi and our company have unreasonable expectations for this year. No money to be made with this product.

 

yikes! Most of my doctors are wanting to see results better than Repatha. They believe that the longer study should make it more positive. If it isn’t we are doomed!!

 

That’s the wishful thinking approach. Reality is that patients on maximally tolerated statins already have most of their protection they will get from ldl lowering. Probably need 50000 patients followed for 5 years to see mortality benefits with PCSK9s. Who will pay for that study? Unfortunately that is what we are dealing with. If it was a significant improvement in Praluent arm then we would have had to stop the trial early. Also if it were very negative we would have stopped it early. A neutral result may as well be very negative. Managed Care will stop covering this class completely. Doctors will feel bamboozled and quickly shut their doors to us. Saturday is right around the corner. Not good!!

 

Time is almost upon us

 

yes...repatha also an EXPENSIVE flop...thanks for nothing...

 

Twas the night before disaster and all through Regeneron. Statisticians working frantically trying to get a positive spin on. No matter how hard they try. Praluent is going to have to say goodbye.

 

Nice poem, go look for another job! No one needs your negative energy. Our outcomes are great, be proud or leave! Overpaid poet

 

Nice poem dick lick. Please tell me we don't have many like you in the sales organization. Talk about a moron.

What do all you naysayers have to say now that the date is out for Praluent?

Yeah, crickets, I thought so

If you don't like it here, leave.

 

Clearly, you are a complete idiot with zero understanding of the data.

 

Hmmm...I guess the other half of your brain isn't working, moron.

 

Guess half your brain isn't working, moron.

 

https://www.msn.com/en-us/money/companies/regeneron-sanofi-cut-heart-drugs-price-to-spur-greater-use/ar-BBK5axf?ocid=spartandhp

Not good.

 

amgen here - we are both screwed as this is a niche drug.
Both companies hired too many reps thinking it would be for pcp markets

 

All you koolaid drinking morons swallow whatever garbage the company gives you to swallow. The results are not great! OP is 100% correct!! That is why we quickly announced a significant drop in cost of Praluent. Up to 69% drop in price possible. That doesn’t scream strength in the data!!!!!!

 

Is the data was strong, we would be raising the price price instead of lowering.

 

Primary endpoint efficacy not impressive at all.
Luckily they stumbled into some benefit with the “all cause mortality.”
Who.knows what that really means at this point.

 

Truth